Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Regulatory News (OKYO)

  • There is currently no data for OKYO

Director's dealing

1 Mar 2013 09:32

RNS Number : 0086Z
West African Minerals Corporation
01 March 2013
 



For immediate release

1 March 2013

West African Minerals Corporation

("WAFM" or the "Company")

Director's dealing

The Board of West African Minerals was informed on 28 February 2013 that Plinian Guernsey Limited ("Plinian") had on the same date transferred for no consideration 312,378 Ordinary Shares in the Company to Allgate Properties S.A. ("Allgate") pursuant to finder's fee arrangements previously agreed between Plinian and Allgate in relation to the Company's Cameroon properties prior to the admission of the Company to AIM. Allgate has agreed to enter into a deed of adherence to the orderly market agreement entered into by Plinian at admission, such that until 8 January 2014, Allgate may only sell the ordinary shares with the prior approval of the Company's nominated adviser and broker. As a consequence of the transfer, Plinian is now interested in 30,925,428 Ordinary Shares representing approximately 10.7 per cent. of the Company's issued share capital. Brad Mills, a director of the Company, is the controlling shareholder and director of Plinian.

Enquiries:

For further information contact:

 

West African Minerals Corporation

Anton Mauve

Managing Director

 

Donna Yoshimatsu

Investor Relations and Corporate Secretary

 

+44 (0) 1624 639396

 

 

+1 (647) 777-4432

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish

Michael Cornish

 

+44 (0)20 7628 3396

Investec Bank PLC (Broker)

Neil Elliot

Mark Wellesley-Wood

 

+44 (0)20 7597 5970

GTH Communications

Toby Hall

Suzanne Johnson Walsh

+44 (0) 20 7822 7493/7492

 

About West African Minerals Corporation

West African Minerals Corporation (AIM: WAFM) is an iron ore mining and exploration group focused on West Africa with interests in iron ore exploration permits in Cameroon and Sierra Leone. Through its 100 per cent owned subsidiary Compagnie Minière du Cameroun SA, WAFM owns six exploration permits in Cameroon covering a total area of approximately 6,000 square kilometres and spanning the coast to the eastern deposits. The Sierra Leone licences comprise five exploration licences with potential for enriched hematite schists typical of the Marampa Group over a total area of approximately 687 square kilometres.

Further information on the Group is available at www.westafricanminerals.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUGUGWWUPWUBG
Date   Source Headline
7th Sep 20221:30 pmRNSResult of AGM
30th Aug 20227:00 amRNSQ4 '22 IND planned followed by P2 with AmbioPharm
19th Aug 20227:00 amRNSNotice of AGM
18th Aug 20222:06 pmRNSSecond Price Monitoring Extn
18th Aug 20222:00 pmRNSPrice Monitoring Extension
16th Aug 20227:00 amRNSAnnual Financial Report
9th Jun 20227:08 amRNSDirector/PDMR Shareholding
20th May 20227:00 amRNSDirector/PDMR Shareholding
19th May 20224:01 pmRNSClosing of Offering
18th May 202210:10 amRNSDirector/PDMR Shareholding
17th May 20227:00 amRNSOKYO Announces Pricing of IPO of ADSs in the U.S.
27th Apr 20227:00 amRNSUpcoming Presentations at Ophthalmic Conference
7th Mar 20227:00 amRNSAdditional Listing
23rd Feb 20227:00 amRNSPatent issued: to treat ocular neuropathic pain
21st Feb 20225:00 pmRNSCLN Conversion, exercise of Warrants, equity issue
15th Feb 20227:00 amRNSSuccessful Pre-IND Meeting with the FDA on OK-101
1st Feb 20227:00 amRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSDirector/PDMR Shareholding
26th Jan 20222:05 pmRNSSecond Price Monitoring Extn
26th Jan 20222:00 pmRNSPrice Monitoring Extension
26th Jan 20227:00 amRNSHalf-year Report
14th Dec 20217:00 amRNSU.S. Patent issued for use of OK-101 to treat DED
13th Dec 20217:00 amRNSOK-101:Anti-inflammatory & Pain-Reducing Potential
6th Dec 20217:00 amRNSIND filing Q3 2022 and Phase 2 initiation Q4 2022
1st Dec 20217:00 amRNSDirectorate Change
19th Oct 20214:41 pmRNSSecond Price Monitoring Extn
19th Oct 20214:35 pmRNSPrice Monitoring Extension
19th Oct 20212:05 pmRNSSecond Price Monitoring Extn
19th Oct 20212:00 pmRNSPrice Monitoring Extension
27th Sep 202112:06 pmRNSResult of AGM
9th Sep 20217:00 amRNSNotice of AGM
1st Sep 20217:00 amRNSDirector/PDMR Shareholding
2nd Aug 202111:32 amRNSAnnual Financial Report
29th Jun 20217:00 amRNSResearch Update
17th Jun 20213:58 pmRNSDirectorate Change
12th May 20217:00 amRNSHolding(s) in Company
7th May 202110:07 amRNSAdditional Listing
5th May 202111:53 amRNSPublication of a Prospectus
28th Apr 20217:00 amRNSPositive Data in an Animal Model using OK-201
29th Mar 20217:00 amRNSAppointment of Chief Scientific Officer
3rd Mar 20217:00 amRNSIssue of Equity
1st Mar 20217:00 amRNSIssue of Equity
23rd Feb 20217:00 amRNSPatent for treating Ocular Pain and Inflammation
19th Jan 20217:00 amRNSFiling patent application for the use of Chemerin
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:37 pmRNSPrice Monitoring Extension
14th Jan 20212:05 pmRNSSecond Price Monitoring Extn
14th Jan 20212:00 pmRNSPrice Monitoring Extension
7th Jan 20217:00 amRNSDirectorate Change
30th Nov 20207:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.